WENDY DAVIS: Open Payments
NPI 1265005110 · RED BLUFF, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,777 in 140 payments from 21 companies in 2025. Trend: 2023 $2,434 · 2024 $2,938 · 2025 $2,777
Food & beverage: $2,777
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 58 | $1,116 |
| Corcept Therapeutics | 7 | $227 |
| Daiichi Sankyo Inc. | 16 | $192 |
| Novo Nordisk Inc | 9 | $167 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $160 |
| Vanda Pharmaceuticals Inc. | 15 | $152 |
| Astellas Pharma US Inc | 4 | $115 |
| Tandem Diabetes Care, Inc. | 3 | $114 |
| GlaxoSmithKline, LLC. | 4 | $75 |
| PFIZER INC. | 3 | $74 |
Products named: UBRELVY, VRAYLAR, MAVYRET, Korlym, INJECTAFER, QULIPTA, JARDIANCE, FANAPT.
Industry payments across CA — which companies pay providers there.
